Patents by Inventor Osamu Kurasawa
Osamu Kurasawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10696651Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: August 9, 2017Date of Patent: June 30, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jun Fujimoto, Xin Liu, Osamu Kurasawa, Terufumi Takagi, Douglas Robert Cary, Hiroshi Banno, Yasutomi Asano, Takuto Kojima
-
Patent number: 10519110Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: October 30, 2018Date of Patent: December 31, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20190169166Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 9, 2017Publication date: June 6, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Jun FUJIMOTO, Xin LIU, Osamu KURASAWA, Terufumi TAKAGI, Douglas Robert CARY, Hiroshi BANNO, Yasutomi ASANO, Takuto KOJIMA
-
Publication number: 20190062274Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Patent number: 10189785Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: April 19, 2016Date of Patent: January 29, 2019Assignee: Takeda Pharmaceuticals Company LimitedInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20180170874Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: April 19, 2016Publication date: June 21, 2018Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Publication number: 20170209452Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: April 11, 2017Publication date: July 27, 2017Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 9655900Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: June 8, 2016Date of Patent: May 23, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
-
Publication number: 20160310494Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: June 8, 2016Publication date: October 27, 2016Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 9388195Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: December 10, 2014Date of Patent: July 12, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
-
Patent number: 9090601Abstract: The present invention relates to a compound represented by the formula (I) or (I?): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.Type: GrantFiled: January 28, 2010Date of Patent: July 28, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Hiroshi Banno, Masaaki Hirose, Osamu Kurasawa
-
Publication number: 20150158882Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: December 10, 2014Publication date: June 11, 2015Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Publication number: 20140235615Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Publication number: 20140228352Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 14, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
-
Patent number: 8691828Abstract: The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: GrantFiled: March 4, 2010Date of Patent: April 8, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Osamu Kurasawa
-
Publication number: 20130029969Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: February 16, 2011Publication date: January 31, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
-
Publication number: 20120040981Abstract: The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.Type: ApplicationFiled: March 4, 2010Publication date: February 16, 2012Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yuya Oguro, Osamu Kurasawa
-
Publication number: 20110003807Abstract: The present invention relates to a compound represented by the formula (I) or (I?): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.Type: ApplicationFiled: January 28, 2010Publication date: January 6, 2011Applicants: Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company LimitedInventors: Hiroshi Banno, Masaaki Hirose, Osamu Kurasawa
-
Patent number: 7795267Abstract: The present invention provides a compound represented by the formula: wherein R1 is —(C?O)—NR7R8 or —(C?O)—OR6, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.Type: GrantFiled: August 26, 2004Date of Patent: September 14, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Kohji Fukatsu, Yutaka Nakayama, Naoki Tarui, Masaaki Mori, Hirokazu Matsumoto, Osamu Kurasawa, Hiroshi Banno
-
Publication number: 20100004238Abstract: The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).Type: ApplicationFiled: December 11, 2007Publication date: January 7, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomoyasu Ishikawa, Hiroshi Banno, Youichi Kawakita, Tomohiro Ohashi, Osamu Kurasawa